Compare MVIS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVIS | NRXS |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6M | 78.9M |
| IPO Year | 2010 | 2023 |
| Metric | MVIS | NRXS |
|---|---|---|
| Price | $1.85 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.25 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.4M | 89.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.91 | 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | $664,000.00 | ★ $3,569,282.00 |
| Revenue This Year | $529.06 | $172.91 |
| Revenue Next Year | $168.46 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.23 | $2.21 |
| 52 Week High | $4.90 | $9.33 |
| Indicator | MVIS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 39.42 |
| Support Level | $0.56 | $5.59 |
| Resistance Level | $4.90 | $7.54 |
| Average True Range (ATR) | 0.34 | 0.35 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 5.99 | 43.67 |
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).